4.0 Article

Expression of the class I interferon-related MxA protein in temporal arteries in polymyalgia rheumatica and temporal arteritis

期刊

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
卷 38, 期 2, 页码 144-148

出版社

TAYLOR & FRANCIS AS
DOI: 10.1080/03009740802448841

关键词

-

资金

  1. Goteborg Medical Society
  2. Swedish Heart-Lung Foundation
  3. Swedish Rheumatism Association
  4. Goteborg Rheumatism Association
  5. Rune och Ulla Amlofs Stiftelse
  6. Syskonen Holmstroms Donationsfond

向作者/读者索取更多资源

Objective: The aim of this study was to assess the expression of the interferon type I (IFN-I)-associated MxA protein in polymyalgia rheumatica (PMR) and temporal arteritis (TA). Methods: Non-inflamed temporal artery biopsies from 11 PMR patients were compared with biopsies from 13 patients given other diagnoses. Coded sections were screened immunocytochemically for MxA protein, CD83, CD68, CD3, and S100 protein. Inflamed temporal artery biopsies from four patients with TA were also investigated. Results: Focal MxA expression was seen in non-inflamed arteries, more frequently in PMR than in controls (p=0.0124). MxA expression was also more common in adventitial dendritic cells (DCs) in PMR (p=0.0124). Activated adventitial DCs were detected in PMR. Focal MxA expression in the inflamed biopsies from the patients with TA was not related spatially to the inflammation. Conclusions: The expression of MxA protein in arteries from patients with PMR and TA shows that non-inflamed and inflamed vessel walls are influenced by IFN-I. Further studies are required to elucidate whether IFN-I plays a role in the initiation of PMR and/or TA, serving as a link between the innate and the adaptive immune responses, as in some other autoimmune disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma

Tajana Tesan Tomic, Josefin Olausson, Annica Wilzen, Magnus Sabel, Katarina Truve, Helene Sjogren, Sandor Dosa, Magnus Tisell, Birgitta Lannering, Fredrik Enlund, Tommy Martinsson, Pierre Aman, Frida Abel

PLOS ONE (2017)

Article Genetics & Heredity

Cell Cycle and Cell Size Dependent Gene Expression Reveals Distinct Subpopulations at Single-Cell Level

Soheila Dolatabadi, Julian Candia, Nina Akrap, Christoffer Vannas, Tajana Tesan Tomic, Wolfgang Losert, Goran Landberg, Pierre Aman, Anders Stahlberg

FRONTIERS IN GENETICS (2017)

Article Medicine, Research & Experimental

Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses

David Svec, Soheila Dolatabadi, Christer Thomsen, Nicole Cordes, Mark Shannon, Paul Fitzpatrick, Goeran Landberg, Pierre Aman, Anders Stahlberg

LABORATORY INVESTIGATION (2018)

Article Oncology

JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma

Soheila Dolatabadi, Emma Jonasson, Malin Linden, Bentolhoda Fereydouni, Karin Backsten, Malin Nilsson, Anna Martner, Amin Forootan, Henrik Fagman, Goran Landberg, Pierre Aman, Anders Stahlberg

INTERNATIONAL JOURNAL OF CANCER (2019)

Article Medicine, Research & Experimental

Requirement for YAP1 signaling in myxoid liposarcoma

Marcel Trautmann, Ya-Yun Cheng, Patrizia Jensen, Ninel Azoitei, Ines Brunner, Jennifer Huellein, Mikolaj Slabicki, Ilka Isfort, Magdalene Cyra, Ruth Berthold, Eva Wardelmann, Sebastian Huss, Bianca Altvater, Claudia Rossig, Susanne Hafner, Thomas Simmet, Anders Stahlberg, Pierre Aman, Thorsten Zenz, Undine Lange, Thomas Kindler, Claudia Scholl, Wolfgang Hartmann, Stefan Froehling

EMBO MOLECULAR MEDICINE (2019)

Article Oncology

Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma

Marcel Trautmann, Magdalene Cyra, Ilka Isfort, Birte Jeiler, Arne Krueger, Inga Gruenewald, Konrad Steinestel, Bianca Altvater, Claudia Rossig, Susanne Hafner, Thomas Simmet, Jessica Becker, Pierre Amana, Eva Wardelmann, Sebastian Huss, Wolfgang Hartmann

MOLECULAR CANCER THERAPEUTICS (2019)

Article Biochemistry & Molecular Biology

FET family fusion oncoproteins target the SWI/SNF chromatin remodeling complex

Malin Linden, Christer Thomsen, Pernilla Grundevik, Emma Jonasson, Daniel Andersson, Rikard Runnberg, Soheila Dolatabadi, Christoffer Vannas, Manuel Luna Santamaria, Henrik Fagman, Anders Stahlberg, Pierre Aman

EMBO REPORTS (2019)

Article Multidisciplinary Sciences

Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone

Ilka Isfort, Sandra Elges, Magdalene Cyra, Ruth Berthold, Marcus Renner, Gunhild Mechtersheimer, Pierre Aman, Olle Larsson, Nancy Ratner, Susanne Hafner, Thomas Simmet, Christoph Schliemann, Claudia Rossig, Uta Dirksen, Inga Gruenewald, Eva Wardelmann, Sebastian Huss, Wolfgang Hartmann, Marcel Trautmann

SCIENTIFIC REPORTS (2019)

Article Cell Biology

Total mRNA Quantification in Single Cells: Sarcoma Cell Heterogeneity

Emma Jonasson, Lisa Andersson, Soheila Dolatabadi, Salim Ghannoum, Pierre Aman, Anders Stahlberg

Article Oncology

FET fusion oncoproteins interact with BRD4 and SWI/SNF chromatin remodelling complex subtypes in sarcoma

Malin Linden, Christoffer Vannas, Tobias Osterlund, Lisa Andersson, Ayman Osman, Mandy Escobar, Henrik Fagman, Anders Stahlberg, Pierre Aman

Summary: FET fusion oncoproteins bind with SWI/SNF complexes and indirectly interact with BRD4, co-localizing on chromatin and interacting with transcription factors and RNA Polymerase II.

MOLECULAR ONCOLOGY (2022)

Article Oncology

FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma

Soheila Dolatabadi, Emma Jonasson, Lisa Andersson, Manuel Luna Santamaria, Malin Linden, Tobias Osterlund, Pierre Aman, Anders Stahlberg

Summary: Myxoid liposarcoma, a type of sarcoma characterized by FET fusion oncogenes, is associated with JAK-STAT signaling. In this study, the researchers found that the FET fusion oncogene FUS-DDIT3 is closely connected to JAK-STAT signaling. They identified genes regulated by both FUS-DDIT3 and JAK1/2 inhibition, and confirmed the targets using chromatin immunoprecipitation sequencing data sets. The findings provide new insights into the molecular mechanisms underlying tumor progression and potential avenues for targeted therapies.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma

Ruth Berthold, Ilka Isfort, Cihan Erkut, Lorena Heinst, Inga Gruenewald, Eva Wardelmann, Thomas Kindler, Pierre Aman, Thomas G. P. Gruenewald, Florencia Cidre-Aranaz, Marcel Trautmann, Stefan Froehling, Claudia Scholl, Wolfgang Hartmann

Summary: Myxoid liposarcoma (MLS), a common subtype of liposarcoma, is characterized by a recurrent chromosomal translocation generating a chimeric FUS-DDIT3 fusion gene. The study reveals that FUS-DDIT3-driven IGF-IR/PI3K/AKT signaling promotes stability and nuclear accumulation of YAP1 via deregulation of the Hippo pathway, and demonstrates substantial cooperative effects of YAP1 and FUS-DDIT3 in the pathogenesis of MLS.

ONCOGENESIS (2022)

Article Biochemistry & Molecular Biology

Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo

Christoffer Vannas, Lisa Andersson, Soheila Dolatabadi, Parmida Ranji, Malin Linden, Emma Jonasson, Anders Stahlberg, Henrik Fagman, Pierre Aman

Summary: Research has shown that different HSP90 inhibitors can have significant differences in therapeutic effects and outcomes for myxoid liposarcoma, with some inhibitors even leading to paradoxical effects. Careful consideration should be given to drug selection and treatment strategies.

BIOMEDICINES (2022)

Article Oncology

FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma

Marcel Trautmann, Jasmin Menzel, Christian Bertling, Magdalene Cyra, Ilka Isfort, Konrad Steinestel, Sandra Elges, Inga Guenewald, Bianca Altvater, Claudia Rossig, Stefan Froehling, Susanne Hafner, Thomas Simmet, Pierre Aman, Eva Wardelmann, Sebastian Huss, Wolfgang Hartmann

CLINICAL CANCER RESEARCH (2017)

暂无数据